Catalog No.
Product Name
Application
Product Information
Citations
-
JNK inhibitor
CC-401 is a second generation ATP-competitive anthrapyrazolone c-Jun N terminal kinase (JNK) inhibitor with potential antineoplastic activity.- Jacob Insua‐Rodriguez, .et al. , EMBO Mol Med, 2018, Oct; 10(10): e9003 PMID: 30190333
-
SAPKs/JNKs activator
Anisomycin is a pyrrolidine antibiotic, acts as an anti-fungal antibiotic which inhibits Protein Synthesis, also is a potent activator of SAPKs/JNKs.- Ken Kobayashi, .et al. , Cell Tissue Res, 2022, Sep;389(3):501-515 PMID: 35748981
- Li Li, .et al. , Cancer Cell Int, 2021, May 13;21(1):260 PMID: 33985519
-
JNK Inhibitor
JNK-IN-8 is the first irreversible JNK inhibitor for JNK1, JNK2 and JNK4 with IC50 of 4.7 nM, 18.7 nM and 1 nM, respectively- Mark P Roberto, .et al. , Immunity, 2021, Aug 10;54(8):1807-1824.e14 PMID: 34380064
-
JNK inhibitor
SP600125 is a JNK inhibitor with IC50=40 nM for JNK-1 and JNK-2 and 90 nM for JNK-3.- Peiling Zhang, .et al. , Regen Biomater, 2023, Sep 7:10:rbad079 PMID: 38020237
- Tetsuya Kouno, .et al. , J Biol Chem, 2022, Jul;298(7):102056 PMID: 35605662
- Mark P Roberto, .et al. , Immunity, 2021, Aug 10;54(8):1807-1824.e14 PMID: 34380064
- Yang PM, .et al. , Am J Cancer Res, 2019, Oct 1;9(10):2120-2139 PMID: 31720078
- Byungki Jang, .et al. , Int J Mol Sci, 2017, Nov; 18(11): 2258 PMID: 29077055
- Yuki Haga, .et al. , PLoS One, 2017, 12(3): e0174153 PMID: 28323861
- Jia-Shiuan Tsai, .et al. , PLoS One, 2016, 11(1): e0147011 PMID: 26751215
- Choe YJ, .et al. , Int J Oncol., 2014, 44(3):761-8. PMID: 24366007
-
JNK inhibitor
AS 602801 is a novel, orally active, Jun Kinase Inhibitor.- Shuai Zhang, .et al. , J Cell Mol Med, 2021, Apr;25(8):4062-4072 PMID: 33609076
- Kuramoto K, .et al. , Anticancer Res, 2018, Sep;38(9):5093-5099 PMID: 30194154
-
JNK Inhibitor IX
TCS JNK 5a is a highly selective inhibitor of JNK2 and JNK3 (pIC50 values are 6.7, 6.5, <5.0 and <4.8 for JNK3, JNK2, JNK1 and p38α respectively).
-
JNK inhibitor
CC-930 is kinetically competitive with ATP in the JNK-dependent phosphorylation of the protein substrate c-Jun and potent against all isoforms of JNK (Ki(JNK1) = 44 ?? 3 nM, IC50(JNK1) = 61 nM, Ki(JNK2) = 6.2 ?? 0.6 nM, IC50(JNK2) = 5 nM, IC50(JNK3) = 5 nM) and selective against MAP kinases ERK1 and p38a with IC50 of 0.48 and 3.4 μM respectively -
MKK4-dependent macropinocytotic Activator
Vacquinol-1 is an MKK4 activator, which rapidly and selectively induces glioma cell death. -
JNK inhibitor
JIP-1 (153-163) is a peptide inhibitor of c-Jun N-terminal kinase (JNK), based on residues 153-163 of JNK-interacting protein-1 (JIP-1). Binds to JNK with affinity in the micromolar range and minimally inhibits p38 and ERK. -
JNK inhibitor
c-JUN peptide is a peptide comprising residues 33 - 57 of the JNK binding (δ) domain of human c-Jun. -
JNK inhibitor
TCS JNK 6o is a ATP-competitive and selective c-Jun N-terminal kinase (JNK) inhibitor. -
JNK3 inhibitor
IQ-1S is a Selective JNK3 inhibitor with IC50 value of 390, 360 and 87 nM for JNK1, 2 and 3 respectively. - Guggulsterone is a plant sterol derived from the gum resin of the tree Commiphora wightii. Guggulsterone inhibits the growth of a wide variety of tumor cells and induces apoptosis through down regulation of antiapoptotic gene products (IAP1, xIAP, Bfl-1/A1, Bcl-2, cFLIP and survivin), modulation of cell cycle proteins (cyclin D1 and c-Myc), activation of caspases and JNK, inhibition of Akt.
-
JNK inhibitor
CC-401 hydrochloride is a second generation ATP-competitive anthrapyrazolone c-Jun N terminal kinase (JNK) inhibitor with potential antineoplastic activity. -
JNK Acticator
Juglanin is a naturally occurring flavonoid isolated from Polygonum aviculare, primarily acting as a JNK activator. It exhibits significant anti-inflammatory, antioxidant, and antitumor properties. Research indicates that Juglanin induces apoptosis and promotes autophagy in human breast cancer cells, making it a valuable reagent for studies on cancer biology and therapeutic interventions. -
JNK Activator
BDE 47 is a JNK activator that targets mitochondria to inhibit mitochondrial oxidative phosphorylation (OXPHOS). This compound decreases mitochondrial membrane potential (MMP) and induces apoptosis in embryonic cells. Additionally, BDE 47 triggers the generation of reactive oxygen species (ROS) and activates the JNK signaling pathway, demonstrating embryonic developmental toxicity in zebrafish models. Its unique properties make it a valuable tool for research on oxidative stress and developmental biology. -
JNK Inhibitor
JNK-IN-17 is a selective and potent inhibitor of c-Jun N-terminal kinase (JNK), demonstrating IC50 values of 0.039 μM and 0.079 μM for JNK1 and JNK3, respectively. It effectively inhibits c-Jun phosphorylation with an IC50 of 0.082 μM in Streptozotocin-induced INS-1 pancreatic islet β cells. Additionally, JNK-IN-17 exhibits low interaction potential, showing an inhibition rate of ≤ 33% on major cytochrome P450 subtypes in human liver microsomes. This compound is valuable for research applications related to neurological and metabolic disorders, including Parkinson's disease. -
JNK Inhibitor
JNK-9L is an ATP-competitive inhibitor targeting c-Jun N-terminal kinases (JNK1 and JNK3), exhibiting IC50 values of 0.099 and 0.148 μM, respectively. This compound effectively inhibits c-jun phosphorylation and reduces reactive oxygen species (ROS) generation induced by Streptozotocin with an IC50 of 0.8 nM. JNK-9L is particularly relevant for research into neurodegenerative diseases, including Parkinson’s disease, facilitating investigations into the therapeutic modulation of JNK pathways. -
JNK3 Inhibitor
JNK3-IN-10 is a selective inhibitor of JNK3, demonstrating an IC50 value of 0.257 nM and exhibiting over 400-fold selectivity over JNK1. This compound effectively disrupts the JNK3-mediated signaling pathway in response to TGF-β1, leading to the inhibition of c-Jun phosphorylation and a reduction in pro-fibrotic marker expression while restoring E-cadherin levels. Its low cytotoxicity profile, along with anti-fibrotic, cytoprotective, and renoprotective properties, makes JNK3-IN-10 a valuable tool for investigating chronic kidney disease, glomerulosclerosis, and adriamycin-induced nephropathy. -
ERK/JNK Inhibitor
Ambuic acid is a potent inhibitor targeting the ERK/JNK pathway, demonstrating notable anti-inflammatory effects. It displays significant antimicrobial activity against Staphylococcus aureus, with an IC50 value of 43.9 μM for the ATCC 6538 strain. Additionally, Ambuic acid inhibits the biosynthesis of cyclic peptide quorum sensing molecules in gram-positive bacteria, making it a valuable compound for research in antimicrobial and anti-inflammatory applications. -
JNK Inhibitor
Cyy-272 is a potent orally active inhibitor of c-Jun N-terminal kinase (JNK), exhibiting IC50 values of 1.25 μM for JNK1, 1.07 μM for JNK2, and 1.24 μM for JNK3. This compound demonstrates significant anti-inflammatory properties by inhibiting JNK phosphorylation, effectively mitigating acute lung injury induced by lipopolysaccharide. Additionally, Cyy-272 reduces inflammation in cardiomyocytes and cardiac tissues affected by high lipid concentrations, contributing to decreased cardiac hypertrophy, fibrosis, and apoptosis. It is valuable for research into the mechanisms of obese cardiomyopathy and related cardiovascular disorders. -
Estrogen Receptor Agonist, Voltage-Gated Sodium Channel Blocker, PI3K-AKT/JNK Signaling Modulator,
Propylparaben sodium acts as a weak estrogen receptor agonist and serves as a voltage-gated sodium channel blocker, while also modulating the PI3K-AKT and JNK signaling pathways. It is known to induce oxidative stress, affecting the estrous cycle and hormone levels, as well as ovarian reserve function. Propylparaben sodium can inhibit the growth of antral follicles and influence the accumulation of steroid hormones in follicle culture media. This compound is suitable for research related to ovarian aging and myocardial ischemia-reperfusion injury. -
JNK2/3 Inhibitor
YL5084 is a covalent inhibitor targeting JNK2 and JNK3, demonstrating selectivity for these isoforms with IC50 values of 70 nM and 84 nM, respectively, while showing significantly reduced activity against JNK1 at 2173 nM. This compound exhibits JNK2-independent antiproliferative effects and effectively induces apoptosis without reliance on JNK2 pathways. YL5084 serves as a valuable tool for research into cellular signaling and cancer biology, particularly in studies focusing on the role of JNK isoforms in tumor growth and survival. -
JNK3 Inhibitor
JNK3 inhibitor-5 is a selective inhibitor targeting JNK3, exhibiting a potent IC50 of 0.379 nM. This compound demonstrates significant neuroprotective activity by safeguarding neuronal cells from amyloid beta-induced apoptosis. Additionally, JNK3 inhibitor-5 is characterized by high cell permeability and is predicted to effectively cross the blood-brain barrier, making it a valuable tool for studying neurological disorders and related therapeutic applications. -
TLR4/JNK/NF-κB Inhibitor
TLR4-IN-2 is an inhibitor targeting TLR4, JNK, and NF-κB pathways. It demonstrates anti-inflammatory properties by reducing nitric oxide production in LPS-stimulated RAW264.7 cells, with an IC50 of 23.2 µM. By inhibiting TLR4 expression and diminishing JNK phosphorylation, TLR4-IN-2 effectively suppresses NF-κB activation and the transcription of inflammation-related genes, leading to lower levels of iNOS, COX-2, and various inflammatory mediators. This compound shows potential for investigating therapeutic strategies in inflammatory diseases such as rheumatoid arthritis and other inflammatory disorders. -
JNK/c-Met Inhibitor
JNK-IN-16 is a potent inhibitor of both JNK and c-Met, exhibiting IC50 values of 72 nM and 120 nM, respectively. This compound demonstrates significant anti-cancer activity, making it valuable for research in cancer biology and therapeutic development. Its dual inhibition profile allows for exploration in signaling pathways associated with tumor progression and metastasis. -
Autophagy inducer
Tomatidine hydrochloride acts as an anti-inflammatory agent by blocking NF-κB and JNK signaling. Tomatidine hydrochloride activates autophagy either in mammal cells or C elegans. -
NF-κB inhibitor
Urolithin B is one of the gut microbial metabolites of ellagitannins, and has anti-inflammatory and antioxidant effects. Urolithin B is also a regulator of skeletal muscle mass. -
antiinflammation agent
Ginsenoside Re (Ginsenoside B2) is an extract from Panax notoginseng. Ginsenoside Re decreases the β-amyloid protein (Aβ). Ginsenoside Re plays a role in antiinflammation through inhibition of JNK and NF-κB. -
JNK inhibitor
CC-90001 is a potent and selective JNK inhibitor. CC-90001 shows 12.9-fold selectivity for JNK1 over JNK2 in a cell-based model. CC-90001 can be used for the research of idiopathic pulmonary fibrosis -
CDK Inhibitor
Aloisine A is a potent cyclin-dependent kinase (CDK) inhibitor, exhibiting IC50 values of 0.15 μM for CDK1/cyclin B, 0.12 μM for CDK2/cyclin A, 0.4 μM for CDK2/cyclin E, and 0.16 μM for CDK5/p35. In addition to its CDK inhibitory effects, Aloisine A also inhibits GSK-3α and GSK-3β with IC50 values of 0.5 μM and 1.5 μM, respectively. Notably, it enhances the activity of wild-type and mutant CFTR with submicromolar affinity through a cAMP-independent mechanism, making it a valuable tool for research related to cystic fibrosis and CFTR-related disorders. -
Apoptosis Inducer
epi-Eriocalyxin A is a diterpenoid compound that serves as an apoptosis inducer in colon cancer cells. It effectively inhibits the activation of ERK1/2 and JNK pathways, leading to the suppression of Bcl-2 expression. This compound is valuable for research focused on cancer treatment and the mechanisms of apoptosis. -
Antiviral Agent
Dendrobine is an alkaloid derived from Dendrobium nobile, primarily targeting viral infections as an antiviral agent. It demonstrates significant antiviral activity against influenza A viruses, exhibiting IC50 values of 3.39 μM, 2.16 μM, and 5.32 μM for strains A/FM-1/1/47 (H1N1), A/Puerto Rico/8/34 H274Y (H1N1), and A/Aichi/2/68 (H3N2), respectively. Additionally, Dendrobine activates the JNK/p38/Nrf2 signaling pathway and possesses various biological properties, including antitumor, anti-inflammatory, and neuroprotective effects, making it valuable in diverse research applications. -
Anticancer Agent
Citropten, also known as 5,7-dimethoxycoumarin, is a coumarin derivative with notable anticancer properties. It demonstrates significant anti-proliferative effects against A2058 and B16 melanoma cell lines, making it a valuable tool in cancer research. Additionally, Citropten exhibits anti-inflammatory activity by modulating the NFκB and MAPK signaling pathways. Its potential antidepressant effects are mediated through interactions with heat shock protein-70, monoamine oxidase-A, and the inhibition of apoptosis. -
MKK7-JNK Activator
MKK7-JNK Activator 1 is a potent activator of the MKK7-JNK signaling pathway. This compound effectively inhibits the proliferation and migration of MDA-MB-468 cells, while also triggering G2/M phase cell cycle arrest and caspase-dependent apoptosis, independent of reactive oxygen species (ROS) production. Notably, MKK7-JNK Activator 1 significantly increases the phosphorylation levels of MKK7 and JNK without affecting ERK or p38 phosphorylation. This reagent is valuable for studying mechanisms relevant to triple-negative breast cancer (TNBC). -
p38/JNK Inhibitor
LL-Z1640-4 is a selective inhibitor of p38 and JNK signaling pathways, demonstrating significant efficacy in attenuating their activation in hepatocellular carcinoma (HCC) cells following MLK4 siRNA transfection. This compound effectively reduces reactive oxygen species (ROS) production associated with MLK4 knockdown and subsequently decreases apoptosis in these HCC cells. LL-Z1640-4 serves as a valuable tool for investigating the roles of p38 and JNK in cancer biology and therapeutic interventions. -
PPAR agonist
Lobeglitazone sulfate is a novel thiazolidinedione and an orally active agonist of peroxisome proliferator-activated receptors (PPARs), with EC50 values of 137.4 nM for PPARγ and 546.3 nM for PPARα. It also acts as an inhibitor of the ERK/JNK/Smad/NF-κB signaling pathways. Lobeglitazone sulfate exhibits anti-inflammatory, anti-diabetic, anti-fibrotic, and anti-atherosclerotic activities, supporting its potential in the treatment of metabolic and inflammatory diseases. - 6-Demethoxytangeretin is a flavonoid compound isolated from *Citrus reticulata* with demonstrated anti-inflammatory and anti-allergic properties. It inhibits IL-6 production and the expression of related genes in human mast cells by modulating the ALK and MAPK signaling pathways. Additionally, 6-Demethoxytangeretin enhances CRE-mediated transcription in hippocampal neurons, indicating potential neuroregulatory effects.
-
Endoplasmic Reticulum Stress Inhibitor
Tauroursodeoxycholate (Tauroursodeoxycholic acid; TDUCA) dihydrate is an inhibitor of endoplasmic reticulum (ER) stress that significantly downregulates pro-apoptotic molecules, including caspase-3 and caspase-12. Additionally, it suppresses ERK signaling, contributing to its cytoprotective and anti-apoptotic effects. -
Neuroprotective agent
(E)-Osmundacetone is a geometric isomer of Osmundacetone, exhibiting notable biological activity. It significantly inhibits the phosphorylation of mitogen-activated protein kinases (MAPKs), including JNK, ERK, and p38, which are key mediators of cellular stress and inflammatory responses. Through this inhibition, (E)-Osmundacetone exerts neuroprotective effects, particularly against oxidative stress-induced neuronal damage. These properties make it a promising compound for research in neurodegenerative diseases and oxidative stress-related conditions.
